Organization
Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute
4 abstracts
Abstract
Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy.Org: Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Colorado Blood Cancer Institute/Sarah Cannon Research Institute,
Abstract
Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies.Org: UCI Health, Medical College of Wisconsin, Maria Sklodowska-Curie National Research Institute of Oncology, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Linear Clinical Research and Sir Charles Gairdner Hospital,
Abstract
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.Org: Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Swedish Cancer Institute, Century Therapeutics, University of Texas MD Anderson Cancer Center, Henry Ford Health System,
Abstract
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.Org: Medical College of Wisconsin, Milwaukee, WI, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland, IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Medicina Specialistica,